AX-0810 is a unique therapeutic approach leading to a potentially disease modifying therapy by targeting the NTCP channel which is responsible for majority of bile acid re-uptake in liver …
ProQR Announces Preclinical Proof of Concept Data ... - ProQR …
2024年5月9日 · ProQR is developing its AX-0810 program targeting NTCP for Cholestatic Diseases and plans to advance the program to the clinic in late 2024/early 2025. ProQR also …
ProQR Announces Initial Pipeline Targets and Highlights …
2023年3月29日 · ProQR today announced AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 as initial pipeline programs.
AX-0810 (AX-0810) - 药物靶点：NTCP_在研适应症：胆汁淤积， …
ProQR专有的Axiomer®RNA编辑平台已在多个临床前体外、类器官和体内模型中证明其活性；在啮齿动物和非人类灵长类动物中观察到高达50%的编辑率。
遗传性疾病创新药物研发商ProQR公布Axiomer™ RNA编辑技术平台的新临床前数据，针对NTCP …
2024年5月8日 · ProQR科学家首次在ADAR RNA编辑领域报告了使用Axiomer™RNA编辑寡核苷酸在体内靶标参与证明（RNA编辑）导致NHPs中生物标志物发生有意义的变化。 该公司AX …
ProQR Announces Preclinical Proof of Concept Data for AX-0810 …
ProQR is developing its AX-0810 program targeting NTCP for Cholestatic Diseases and plans to advance the program to the clinic in late 2024/early 2025. ProQR also expects the following …
ProQR Therapeutics NV
In October, ProQR presented at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, highlighting its Axiomer technology platform and AX-0810, the Company’s …
ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with …
ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic...
ProQR Announces Preclinical Proof of Concept Data for AX-0810 …
2024年5月8日 · By specifically affecting the main transporter for bile acids reuptake from the portal vein circulation to the liver, called NTCP (Na-taurocholate transporting polypeptide, …
H.C. Wainwright上调ProQR股票目标价至$12，维持买入评级
2025年3月17日 · 人类遗传学数据显示，NTCP的一种变体可以限制胆汁酸的摄取，这进一步支持了ProQR方法的潜在疗效。 分析师还注意到，来自人源化小鼠和非人灵长类动物（NHPs）的 …